Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis.

SARS-CoV-2 infection coronavirus disease 2019 vaccine effectiveness

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
21 Jan 2022
Historique:
received: 17 11 2021
revised: 29 12 2021
accepted: 30 12 2021
entrez: 26 2 2022
pubmed: 27 2 2022
medline: 27 2 2022
Statut: epublish

Résumé

(1) Background: The objective of this study was to assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease and transmission in the pre-Delta era. The evaluation was narrowed to two mRNA vaccines and two modified adenovirus-vectored vaccines. (2) Methods: The overall risk of any SARS-CoV-2 infection confirmed by positive real-time Polymerase Chain Reaction (PCR) test was estimated in partially and fully vaccinated individuals. The evidence synthesis was pursued through a random-effects meta-analysis. The effect size was expressed as relative risk (RR) and RRR (RR reduction) of SARS-CoV-2 infection following vaccination. Heterogeneity was investigated through a between-study heterogeneity analysis and a subgroup meta-analysis. (3) Results: The systematic review identified 27 studies eligible for the quantitative synthesis. Partially vaccinated individuals presented a RRR = 73% (95%CI = 59-83%) for positive SARS-CoV-2 PCR (RR = 0.27) and a RRR=79% (95%CI = 30-93%) for symptomatic SARS-CoV-2 PCR (RR = 0.21). Fully vaccinated individuals showed a RRR = 94% (95%CI = 88-98%) for SARS-CoV-2 positive PCR (RR = 0.06) compared to unvaccinated individuals. The full BNT162b2 vaccination protocol achieved a RRR = 84-94% against any SARS-CoV-2-positive PCR and a RRR = 68-84% against symptomatic positive PCR. (4) Conclusions: The meta-analysis results suggest that full vaccination might block transmission. In particular, the risk of SARS-CoV-2 infection appeared higher for non-B.1.1.7 variants and individuals aged ≥69 years. Considering the high level of heterogeneity, these findings must be taken with caution. Further research on SARS-CoV-2 vaccine effectiveness against emerging SARS-CoV-2 variants is encouraged.

Identifiants

pubmed: 35214615
pii: vaccines10020157
doi: 10.3390/vaccines10020157
pmc: PMC8879968
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Ministry of Health Italy

Références

Open Forum Infect Dis. 2021 Sep 17;8(10):ofab465
pubmed: 34646910
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Rev Esp Salud Publica. 2021 Apr 29;95:
pubmed: 33913444
Clin Infect Dis. 2021 Jul 03;:
pubmed: 34216472
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
Clin Infect Dis. 2022 Jan 7;74(1):59-65
pubmed: 33704435
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
MMWR Morb Mortal Wkly Rep. 2021 May 07;70(18):674-679
pubmed: 33956782
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
Nat Med. 2021 Aug;27(8):1370-1378
pubmed: 34108716
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Lancet Infect Dis. 2021 Nov;21(11):1529-1538
pubmed: 34174193
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
Mil Med Res. 2020 Feb 29;7(1):7
pubmed: 32111253
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 May 20;384(20):1962-1963
pubmed: 33755374
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
Res Synth Methods. 2010 Apr;1(2):112-25
pubmed: 26061377
Emerg Infect Dis. 2021 Oct;27(10):2595-2603
pubmed: 34314670
Stat Med. 2002 Sep 30;21(18):2641-52
pubmed: 12228882
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
Res Synth Methods. 2012 Sep;3(3):214-23
pubmed: 26062164
BMC Med. 2021 Oct 18;19(1):275
pubmed: 34663326
Elife. 2021 Apr 08;10:
pubmed: 33830018
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Clin Infect Dis. 2021 Sep 15;73(6):e1376-e1379
pubmed: 33900384
JAMA Netw Open. 2021 Nov 1;4(11):e2132540
pubmed: 34726743
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Stat Med. 2004 Jun 15;23(11):1663-82
pubmed: 15160401
Lancet Infect Dis. 2021 Nov;21(11):1539-1548
pubmed: 34174190
MMWR Morb Mortal Wkly Rep. 2021 Mar 19;70(11):396-401
pubmed: 33735160
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Lancet Infect Dis. 2021 Jul;21(7):890-891
pubmed: 33930321
Lancet. 2021 Mar 6;397(10277):875-877
pubmed: 33610193

Auteurs

Angela Meggiolaro (A)

Italian Ministry of Health, General Directorate for Health Prevention, Viale Ribotta 5, 00144 Rome, Italy.

Monica Sane Schepisi (M)

Italian Ministry of Health, General Directorate for Health Prevention, Viale Ribotta 5, 00144 Rome, Italy.

Georgios F Nikolaidis (GF)

IQVIA, 210 Pentonville Rd, London N1 9JB, UK.

Daniele Mipatrini (D)

Italian Ministry of Health, General Directorate for Health Prevention, Viale Ribotta 5, 00144 Rome, Italy.

Andrea Siddu (A)

Italian Ministry of Health, General Directorate for Health Prevention, Viale Ribotta 5, 00144 Rome, Italy.

Giovanni Rezza (G)

Italian Ministry of Health, General Directorate for Health Prevention, Viale Ribotta 5, 00144 Rome, Italy.

Classifications MeSH